Back to Archived Journals » Research and Reports in Transdermal Drug Delivery » Volume 2

Long-term safety, efficacy, and patient acceptability of the tulobuterol patch

Authors Ichikawa T, Sugiura H 

Received 13 February 2013

Accepted for publication 9 April 2013

Published 30 April 2013 Volume 2013:2 Pages 9—18

DOI https://doi.org/10.2147/RRTD.S34031

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3



Tomohiro Ichikawa,1 Hisatoshi Sugiura2

1Third Department of Internal Medicine, Wakayama Medical University, School of Medicine, Wakayama, 2Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan

Abstract: The tulobuterol patch contains a β2-adrenergic agonist, is the first transdermal bronchodilator, and was developed in Japan. It relies on a matrix-type transdermal delivery system that contains both crystallized and molecular forms of tulobuterol. This delivery system enables the drug content to be released steadily over 24 hours. When the tulobuterol patch is applied to the skin at bedtime, the serum concentration of tulobuterol peaks in the early morning, suppressing the morning dip in pulmonary function. This pharmacological property also prevents steep increases in plasma drug levels, which reduces the risk of adverse events. Because the tulobuterol patch is easy to use and requires only once-daily application, treatment adherence in patients using the patch is superior to that of other therapies. The clinical efficacy of the patch in patients with asthma and chronic obstructive pulmonary disease at any age has been established in many clinical studies since launch in 1998, and the product has a good safety profile. Therefore, the tulobuterol patch is currently used for the long-term treatment of patients with asthma and chronic obstructive pulmonary disease. Here we review the characteristics of the tulobuterol patch and the results of clinical trials that have investigated the effects of the patch on pulmonary function, quality of life, and adherence. We also discuss the usefulness of the tulobuterol patch in clinical practice.

Keywords: tulobuterol patch, long-acting β2-agonist, crystal reservoir system, chronotherapy, asthma, chronic obstructive pulmonary disease

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.